RedHill Biopharma Ltd.
RDHL
$2.07
-$0.065-3.04%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -2.59M | -2.59M | -1.54M | -1.54M | -13.54M |
| Total Depreciation and Amortization | 100.50K | 100.50K | 209.00K | 209.00K | 202.50K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 818.00K | 818.00K | -2.70M | -2.70M | 7.95M |
| Change in Net Operating Assets | 79.50K | 79.50K | 947.00K | 947.00K | -3.63M |
| Cash from Operations | -1.59M | -1.59M | -3.09M | -3.09M | -9.02M |
| Capital Expenditure | -4.00K | -4.00K | -500.00 | -500.00 | -2.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | 7.50K |
| Cash from Investing | -4.00K | -4.00K | -500.00 | -500.00 | 5.50K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -111.00K | -111.00K | -207.00K | -207.00K | -293.00K |
| Issuance of Common Stock | 0.00 | 0.00 | 4.13M | 4.13M | 4.43M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 369.50K | 369.50K | 25.50K | 25.50K | 4.18M |
| Cash from Financing | 258.50K | 258.50K | 3.95M | 3.95M | 8.31M |
| Foreign Exchange rate Adjustments | 7.50K | 7.50K | -3.00K | -3.00K | -9.50K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.33M | -1.33M | 854.00K | 854.00K | -713.50K |